Nervous Disorder TRIZ Cases

Inhibiting BRI3 blocks M2 monocyte trafficking to the central nervous system, reducing cytokine expression and adverse neuroinflammation.

Segmenting MFG-E8 into NP-011 removes non-functional domains, reducing TGF-β expression and treating liver fibrosis.

Humanized anti-Abeta antibodies maintain optimal serum concentrations through specific subcutaneous or intravenous administration schedules.

Substituted N-phenylacetamides inhibit the P2X4 receptor, addressing the lack of effective compounds for chronic pain and inflammatory diseases.

Extracting Gpld1 from blood factors rejuvenates hippocampal neurogenesis, resolving age-related cognitive decline without exercise complexity.

Modular FLAP modulator compounds inhibit leukotriene-mediated diseases by optimizing efficacy and specificity through structural parameter changes.

Amide compounds improve brain-to-serum ratios to treat neurodegenerative diseases without peripheral adverse effects.

Conjugating interferon beta with Fc fragments extends serum half-life while maintaining in vivo activity.

Fasudil inhibits Rho kinase to activate neuronal survival pathways and improve motor function in amyotrophic lateral sclerosis models.

Position 3 modifications convert cytotoxic quinones into safe PPARγ modulators.

NMDA receptor blockers increase 20S proteasome activity, reducing oxidatively damaged protein accumulation that drives aging and associated diseases.

Segmented release profiles deliver rapid analgesia while antagonists counteract nausea and dizziness.

Engineered latent guide RNAs resolve low adenosine editing specificity in LRRK2 by forming structured scaffolds.

Extracting the Fc region from superagonistic antibodies prevents target cell elimination while maintaining efficient T cell proliferation.

Optimized sodium chloride levels with acetate buffers prevent aggregation while maintaining therapeutic efficacy.

Optimizing pH between 4 and 7 resolves formulation stability issues while maintaining treatment efficiency for chronic disease management.

Genetic testing identifies specific nucleotide variations to select folate treatments, resolving low efficacy in treatment-resistant depression cases.

Anti-PHF-tau antibodies bind phosphorylated tau epitopes to inhibit seeding and prevent disease spreading.

Combining palmitoyl ethanolamide with natural fatty acid amide hydrolase inhibitors reduces neuropathic pain without synthetic side effects.

Monoclonal antibodies bind specific tau epitopes to inhibit aggregation, addressing inadequate targeting of neurodegenerative pathology.

Dendritic cell carriers deliver IL-13Rα2 peptides across the blood-brain barrier to overcome poor treatment effectiveness in glioma.

Human-specific TDP-43 antibodies minimize human anti-mouse antibody responses while maintaining high binding affinity through parameter changes.

Potassium channel blockers stabilize mitochondrial DNA in POLG-related diseases, replacing unproven vitamin therapies with evidence-based curative treatment.

Segmenting biomarkers into six functional groups reduces measurement complexity while evaluating glutamate excitotoxicity and mitochondrial function.

A triphenylphosphine-modified sertraline derivative induces mitophagy to remove damaged mitochondria.

Specific Limosilactobacillus reuteri strain LM1063 restores gut microbiota balance disrupted by sleep disorders, supporting metabolic health management.

Chimeric proteins targeting SIRP1alpha overcome Myc-driven cancer immune evasion by blocking inhibitory signals and recruiting macrophages.

Composite PEGylated and polysialic acid conjugated C1 esterase inhibitor resolves short half-life bottleneck by extending serum duration.

A diagnostic kit uses protein kinase C activators to stimulate cells and measure phosphorylated MAP kinase ratios for biomarker detection.

Anti-N3pGlu antibodies clear amyloid plaques rapidly while reducing ARIA adverse events through selective epitope targeting.

Interchain disulfide bonds in modified T cell receptors prevent mismatched pairing, ensuring correct alpha-beta chain association for precise cancer targeting.

Segmenting Tau protein into specific epitopic regions creates targeted peptide immunogens that induce high specificity antibodies.

Baclofen and sorbitol combinations modulate PMP22 expression to restore myelination, addressing chronic neuromuscular degeneration.

A biodegradable polymer scaffold uses a secondary coating to maintain structural integrity during mechanical stretching.

Optimized synthesis parameters and selective purification eliminate toxic impurities from isoindole derivatives, resolving low yield and isolation difficulties.

Composite herbal formulation resolves side effect trade-offs by providing non-cytotoxic neuroprotection without liver toxicity.

Modified G protein-coupled receptors express in neurons to enable targeted neuronal silencing upon administration of a specific exogenous agonist.

GLYX-13 peptide selectively modulates NMDA receptors, resolving the contradiction between therapeutic efficacy and severe side effects in depression treatment.

Bee venom phospholipase A2 polypeptide activates regulatory T cells to restore immune tolerance.

Dendritic cell vaccine presents alpha-synuclein epitopes to generate targeted antibodies.

Administering a fused protein composition of truncated MOG, MBP, and PLP sequences depletes autoimmune T cells to treat demyelinating diseases.

Antibody-drug conjugates target MMP-12-expressing cells, resolving low potency and specificity of small molecule inhibitors.

Droxidopa converts to norepinephrine to reduce chronic pain and fatigue in fibromyalgia patients.

Enteric-coated biguanide compositions target specific intestinal regions to modulate hormonal profiles and reduce systemic lactic acidosis risk.